POTN is very undervalued IMO, as I am expecting revenues to show sequential quarterly increases over the next several years with FDA issues and fraudulent shareholder issues resolved, and uplisting to OTCQB. We should see the normal pattern for a stock with increasing revs in a rapid growth sector of up days followed by consolidation, and more up days.